Abstract 1671P
Background
The rise of the internet has transformed communication and healthcare, allowing easy access to sensitive medical test results. However, this practice lacks regulation. Breast cancer, the most common cancer in women, has seen improved survival rates, leading to more individuals living with the disease. Patients accessing their results online can pose challenges for oncologists due to the anxiety stemming from this constant access. Studies show conflicting outcomes regarding the emotional impact of this access, ranging from increased patient engagement to heightened anxiety. This study aims to investigate whether online receipt of sensitive results can worsen the emotional health of oncology patients, for instance, by intensifying anxiety symptoms.
Methods
This cross-sectional study employed a questionnaire with four sections to assess patients diagnosed with breast cancer within five years. The questionnaire covered demographic information, online test result access habits, anxiety levels during result anticipation, and validated screening tools for personality disorders (PID-5-BF), anxiety (GAD-7), and depression (PHQ-9). Sample size estimation for confidence interval calculations targeted 385 patients. The current analysis includes data from 198 respondents.
Results
Among the 198 participants, 196 (99%) were female, with only 2 (1%) being male. The majority (75.3%) received their breast cancer diagnosis within the past 1 to 5 years. In terms of cancer staging, 41.4% had early-stage disease (Stages I-III), while 57.6% had advanced-stage disease (Stage IV). Concerning online result access, 25.3% reported infrequent online result checks, while 74.2% confirmed habitual checking. During result anticipation, 64.6% expressed anxiety, primarily described as mild (62.2%). Statistical analyses indicated no significant association between online result access behavior and anxiety levels (p=0.609), anxiety disorders (p=0.411), or depressive disorders (p=0.484).
Conclusions
This interim analysis did not reveal a correlation between receiving potentially sensitive test results online and patient anxiety. Recruitment is ongoing and on target to produce a final analysis in the near future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1636P - Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Presenter: Renée Bultijnck
Session: Poster session 11
1637P - Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
Presenter: Neeraj Agarwal
Session: Poster session 11
1638P - Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age
Presenter: Neal Shore
Session: Poster session 11
1639P - Self efficacy in people with prostate cancer in the UK: A large, digital survey
Presenter: Joe O'Sullivan
Session: Poster session 11
1640P - Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients
Presenter: Ziyun Wang
Session: Poster session 11
1641P - Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
Presenter: Christos Kyriakopoulos
Session: Poster session 11
1642P - Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis
Presenter: Charles Vauchier
Session: Poster session 11
1643P - Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Presenter: Bicky Thapa
Session: Poster session 11
1644P - PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Lana Broer
Session: Poster session 11
1645P - Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
Presenter: Marta Garcia De Herreros
Session: Poster session 11